ReviewFrontiers in immunology2018
Combination Strategies to Optimize Efficacy of Dendritic Cell-Based Immunotherapy.
Review in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 73 citations in OpenAlex.
- Reprogramming dendritic cells to overcome tumor-mediated immune suppression.Frontiers in immunology · 2026Review
- Immunotherapy combined with radiotherapy for advanced non-small cell lung cancer: Current status and challenge (Review).Oncology letters · 2025Review
- Article
- Cracking the Codes behind Cancer Cells' Immune Evasion.International journal of molecular sciences · 2024Review
- Dendritic cell-based immunotherapy in non-small cell lung cancer: a comprehensive critical review.Frontiers in immunology · 2024Review
- Targeting lymph node delivery with nanovaccines for cancer immunotherapy: recent advances and future directions.Journal of nanobiotechnology · 2023Review
- Biomaterials Facilitating Dendritic Cell-Mediated Cancer Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Review
- Enhanced anti-tumor immunity of vaccine combined with anti-PD-1 antibody in a murine bladder cancer model.Investigative and clinical urology · 2023Article
- Review
- A Novel Therapeutic Tumor Vaccine Targeting MUC1 in Combination with PD-L1 Elicits Specific Anti-Tumor Immunity in Mice.Vaccines · 2022Article
- Dendritic Cell-Based Immunotherapy in Multiple Myeloma: Challenges, Opportunities, and Future Directions.International journal of molecular sciences · 2022Review
- Progranulin mediates immune evasion of pancreatic ductal adenocarcinoma through regulation of MHCI expression.Nature communications · 2022Article
- A NovelJournal of immunology research · 2022Article
- Therapeutic implications of the tumor microenvironment in ovarian cancer patients receiving PD-1/PD-L1 therapy.Frontiers in immunology · 2022Review
- Immunotherapy for EGFR-mutant advanced non-small-cell lung cancer: Current status, possible mechanisms and application prospects.Frontiers in immunology · 2022Review
- Cholesterol modified DP7 and pantothenic acid induce dendritic cell homing to enhance the efficacy of dendritic cell vaccines.Molecular biomedicine · 2021Article
- Dendritic Cells and Cancer Immunotherapy: The Adjuvant Effect.International journal of molecular sciences · 2021Review
- Local Therapies and Modulation of Tumor Surrounding Stroma in Malignant Pleural Mesothelioma: A Translational Approach.International journal of molecular sciences · 2021Review
- Activity-regulated cytoskeleton-associated protein/activity-regulated gene 3.1 (Arc/Arg3.1) enhances dendritic cell vaccination in experimental melanoma.Oncoimmunology · 2021Article
- Dendritic cell vaccine immunotherapy; the beginning of the end of cancer and COVID-19. A hypothesis.Medical hypotheses · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dendritic cells (DCs) are antigen-presenting cells (APCs) that are essential for the activation of immune responses. In various malignancies, these immunostimulatory properties are exploited by DC-therapy, aiming at the induction of effective anti-tumor immunity by vaccination with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.